Loading...
•
Sep 30, 2023
Janux Q3 2023 Earnings Report
Reported financial results for the third quarter ended September 30, 2023.
Key Takeaways
Janux Therapeutics reported $349.7 million in cash, cash equivalents, and short-term investments at the end of the third quarter 2023. Enrollment is ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors. A net loss of $11.6 million was reported for the quarter ended September 30, 2023.
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer.
Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors.
Update on clinical programs expected in 2024.
Cash and investments projected to support current operating plan through 2027.
Forward Guidance
Janux projects that current cash and investments will be sufficient to fund the current operating plan through 2027 to generate Phase 1b data for PSMA and EGFR-TRACTr programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...